Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.14.5529

Liposome-mediated Induction of Apoptosis of Human Hepatoma Cells by C-Myc Antisense Phosphorothioate Oligodeoxynucleotide and 5-Fluorouracil  

Yuan, Yuan (The First Hospital of Lanzhou University)
Cai, Hui (Gansu Provincial Hospital)
Yang, Xiao-Jun (Gansu Provincial Hospital)
Li, Wei (Gansu Provincial Hospital)
He, Jin (Gansu Provincial Hospital)
Guo, Tian-Kang (Gansu Provincial Hospital)
Chen, Yi-Rong (The First Hospital of Lanzhou University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.14, 2014 , pp. 5529-5533 More about this Journal
Abstract
Background: The aim of this study was to investigate the effect of a c-myc antisense oligodeoxynucleotide and 5-fluorouracil on the expression of c-myc, invasion and proliferation of HEPG-2 liver cancer cells. Materials and Methods: HEPG-2 cells were treated with lipiosome-mediated c-myc ADSON and 5-fluorouracil. The proliferation inhibition rate and invasion were measured by MTT and invasion assay, respectively. Cell apoptosis was detected by flow cytometry and expression of c-myc by RT-PCR and immunohistochemistry. Results: The proliferation inhibition rate was significantly higher in the antisense oligodeoxynucleotide added-5-fluorouracil group than single antisense oligodeoxynucleotide or 5-fluorouracil group (p<0.05). G0/G1 cells in the antisense oligodeoxynucleotide group and S cells in the 5-fluorouracil groups were significantly increased than that in the control group, respectively (P<0.01). The amplification strips of PCR products in 5-FU, ASODN and combination groups were significantly weaker than that in the control group (P<0.01). The percentage of c-myc-protein-positive cells were significantly lower in antisense oligodeoxynucleotide, 5-fluorouracil and combination groups than that in the control group (P<0.01). Conclusions: A liposome-mediated c-myc antisense oligodeoxynucleotide and 5-fluorouracil can inhibit the proliferation and invasion of liver cancer cells by reducing the expression of c-myc. A c-myc antisense oligodeoxynucleotide can increase the sensitivity of liver cancer cells to 5-fluorouracil and decrease the dosage of the agent necessary for efficacy, providing an experimental basis for the clinical therapy of liver cancer.
Keywords
C-myc; antisense oligodeoxynucleotide; 5-fluorouracil; hepatoma carcinoma cell; apoptosis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Jain M, Arvanitis C, Chu K, et al (2002). Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science, 297, 102-4.   DOI   ScienceOn
2 Jansen B, Zangemeister-Wittke U (2002). Antisense therapy for cancer--the time of truth. Lancet Oncol, 3, 672-83.   DOI
3 Jin J, Huang M, Wei HL et al (2002). Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel (7402). World J Gastroenterol, 8. 1029-34.
4 Karlsson A, Giuriato S, Tang F, et al (2003). Genomically complex lymphomas undergo sustained tumor regression upon MY inactivation unless they acquire novel chromosomal translocations. Blood, 101, 2797-803.   DOI
5 Lin CP, Liu CR, Lee CN, et al (2010). Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol, 2. 16-20.
6 Manner J, Radlwi mmer B, Hohenberger P, et al (2010). MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol, 176, 34-9.   DOI
7 Monia BP (1997). First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des, 12, 327-39.
8 Parkin DM, Whelan SL, Ferlay J, et al (1997). eds.:Cancer Incidence in Five Continents. Volume VII. Lyon, France:International Agency for Research on Cancer
9 Pastorino F, Mumbengegwi DR, Ribatti D, et al (2008). Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release, 126, 85-94.   DOI
10 Wang B, Hikosaka K, Sultana N, et al (2012). Liver tumor formation by a mutant retinoblastoma protein in the transgenic mice is caused by an upregulation of c-My target genes. Biochem Biophys Res Co mmun, 417, 601-6.   DOI
11 Wang C, Lisanti MP, Liao DJ (2011). Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1- CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle, 10, 57-67.   DOI
12 Wu SL, Sun ZJ, Yu L, et al (2004). Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol, 10, 3048-52.
13 Yang Y, Lv QJ, Du QY, et al (2005). Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol, 11, 2491-6.   DOI
14 Yochum GS, Sherrick CM, Macpartlin M, et al (2010). A betacatenin/ TCF- coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers. Proc Natl Acad Sci USA, 107, 145-50.   DOI
15 Doe MR, Ascano JM, Kaur M, et al (2012). Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res, 72. 949-57.   DOI
16 Albihn A, Johnsen JI, Henriksson MA (2010). MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res, 107, 163-224   DOI
17 American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society, 2012. Available online. Last accessed November 23, 2012.
18 Barathidasan R, Pawaiya RS, Rai RB, et al (2013). Upregulated myc expression in n-methyl nitrosourea (MNU)-induced rat ma mmary tumours. Asian Pac J Cancer Prev, 14, 4883-9.   DOI
19 Fang YQ, Sun HK, Zhai J, et al (2011). Antitumor Activity of NF-kB Decoy Oligodeoxynucleotides in a Prostate Cancer Cell Line. Asian Pacific J Cancer Prev, 12, 2721-6.
20 Guo WQ, Li LZ, He ZY, et al (2013). Anti-proliferative Effects of Atractylis lancea (Thunb.) DC. via Down-regulation of the c-myc/hTERT/telomerase pathway in Hep-G2 cells. Asian Pac J Cancer Prev, 14, 6363-7.   과학기술학회마을   DOI
21 Hayashi D (1994). Study on the expression of oncogene mRNA in hepatocellular carcinoma using in situ hybridization technique. Nihon Geka Gakkai Zasshi. 95, 814-22.
22 Hemann MT, Bric A, Teruya-Feldstein J, et al (2005). Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 436, 807-11.   DOI
23 Howlader N, Noone AM, Krapcho M, et al (2011), eds.:SEER Cancer Statistics Review, 1975-2008. Bethesda, Md: National Cancer Institute, 2011. Also available online. Last accessed July, 31, 2012.